Sage Therapeutics Brass Sued Over Drug Candidate Claims

By Katryna Perera · May 14, 2025, 9:00 PM EDT

The top brass of Sage Therapeutics Inc. have been hit with a shareholder derivative suit in New York federal court alleging they misled investors about the safety, efficacy, durability and commercial...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Matton v. Greene et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

May 13, 2025

Recent Articles By Katryna

May 14, 2025
10th Circ. Chilly To Biotech's SEC Asset Freeze Challenge
May 06, 2025
Investors Sue West Pharma Over Post-COVID Stock Losses
May 01, 2025
CFPB, Lenders Float Deal To Vacate Medical Debt Rule
April 02, 2025
BakerHostetler Adds Ex-Federal Prosecutor As Partner
March 19, 2025
AI Chatbot Co. LivePerson Beats Shareholder Suit For Good
March 12, 2025
SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval
March 12, 2025
Mallinckrodt Investors Ask NJ Court To Approve $46M Deal
March 05, 2025
SEC Asks To Toss Subpoena Suit Against Telehealth Co.
February 14, 2025
Digital Health Co. Beats Some Claims In SPAC Investor Suit
February 12, 2025
Bausch Health Beats Suit Over 'Faking' Financial Stability